Xavier Leleu, MD, PhD
Xavier Leleu, MD, PhD, is the head of the Department of Haematology and the Myeloma Clinic at Hôpital La Mileterie, in Poitiers, France.
Articles
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Phase 3 IRAKLIA Trial Compares On-Body vs IV Isatuximab in RRMM: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).
